Literature DB >> 25588571

Burden of blood transmitted infections in substance users admitted for inpatient treatment in Singapore and the associated factors.

Rochelle Melina Kinson1, Song Guo, Yi Min Wan, Victoria Manning, Hui Chin Teoh, Kim Eng Wong.   

Abstract

INTRODUCTION: There is paucity of local data on the prevalence of blood transmitted infections (BTIs), such as hepatitis B, hepatitis C and human immunodeficiency virus (HIV) infections, among illicit drug users. This study aimed to examine the prevalence of BTIs among substance dependent inpatients and identify the factors associated with BTIs.
METHODS: We conducted a retrospective analysis of clinical notes of 170 inpatients with a diagnosis of substance dependence who were admitted at the National Addictions Management Service, Singapore, between 1 June 2009 and 31 May 2010.
RESULTS: Majority of the 170 inpatients were male (88.2%) and Chinese (58.2%). The mean age of the patients was 43.1 years, and the main drug of abuse was opioids (86.5%). BTIs were found in 70 (41.2%) inpatients; the prevalence of hepatitis B, hepatitis C and HIV infections was 3.7%, 39.6% and 0%, respectively. Lifetime intravenous drug use, but not needle-sharing, was more common among inpatients who were positive for BTIs (p < 0.01). Logistic regression analysis showed that lifetime intravenous drug use (OR 4.3, 95% CI 1.7- 10.8, p < 0.01) was the only significant predictor of BTIs.
CONCLUSION: A large proportion (41.2%) of the substance users seeking help was positive for at least one BTI. Lifetime intravenous drug users were found to be more than four times more likely to have a BTI. Early detection and prevention is essential to improve prognosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25588571      PMCID: PMC4350474          DOI: 10.11622/smedj.2014199

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  26 in total

1.  Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco.

Authors:  J A Hahn; K Page-Shafer; P J Lum; K Ochoa; A R Moss
Journal:  Hepatology       Date:  2001-07       Impact factor: 17.425

Review 2.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.

Authors:  Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt
Journal:  Lancet       Date:  2011-07-27       Impact factor: 79.321

3.  Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment.

Authors:  M D Stein; J Maksad; J Clarke
Journal:  Drug Alcohol Depend       Date:  2001-02-01       Impact factor: 4.492

4.  Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia.

Authors:  Anna Doab; Carla Treloar; Gregory J Dore
Journal:  Clin Infect Dis       Date:  2005-04-15       Impact factor: 9.079

Review 5.  Epidemiology of hepatitis C virus infection among injecting drug users in Australia.

Authors:  N Crofts; D Jolley; J Kaldor; I van Beek; A Wodak
Journal:  J Epidemiol Community Health       Date:  1997-12       Impact factor: 3.710

6.  Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland.

Authors:  S A Villano; D Vlahov; K E Nelson; C M Lyles; S Cohn; D L Thomas
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

7.  Hepatitis B virus infection and vaccination among young injection and non-injection drug users: missed opportunities to prevent infection.

Authors:  Irene Kuo; Susan G Sherman; David L Thomas; Steffanie A Strathdee
Journal:  Drug Alcohol Depend       Date:  2004-01-07       Impact factor: 4.492

Review 8.  Systematic review of HIV and HCV infection among drug users in China.

Authors:  Y-P Bao; Z-M Liu
Journal:  Int J STD AIDS       Date:  2009-06       Impact factor: 1.359

9.  Seroprevalence and risk factors associated with HTLV-I/II infection in injection drug users in northern New Jersey.

Authors:  R C Freeman; G M Rodriguez; J F French
Journal:  J Addict Dis       Date:  1995

10.  How big is the financial burden of hepatitis B to society? A cost-of-illness study of hepatitis B infection in Singapore.

Authors:  S C Ong; S G Lim; S C Li
Journal:  J Viral Hepat       Date:  2009-01       Impact factor: 3.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.